Navigation Links
Cancer Research UK Offers New Hope To Cancer Patients

In a new clinical development partnership being launched by the Cancer Research UK, and its commercial arm, Cancer Research Technology (CRT) plans to take up// drug candidates that pharmaceuticals companies have ‘deprioritised’ for not showing enough commercial promise following their preclinical studies. By this they plan to develop new treatments from anti-cancer drugs that have been shelved by pharmaceutical and biotechnology companies.

Under the scheme, companies will hand over molecules that once showed promise, but were never developed, and CRT will take on the clinical trials for those molecules. It is proposed that the Pharma and biotech firms will keep the intellectual property rights to the molecules they had shelved. After CRT has done clinical trials, the company will be given the option to take the molecule back and develop it themselves, or to leave it in the hands of the CRT scientists.

Harpal Kumar CRT chief executive hopes that the scheme that would cost up to £2 million a year, will help to identify at least five more drug molecules annually, to add to CRT’s current portfolio of around 25 licensed molecules in the clinic.Kumar sounding very optimistic said that they Hopefully would be flooded with opportunities, he told reporters. Kumar was also keen to state a point that the project was not being developed as a money-spinner for the charity, but he said that the Cancer Research UK does expects to receive a share of any financial return made by the companies.

Richard Tiner, medical director of the Association of the British Pharmaceutical Industry (ABPI) said that he personally could saw no reason for the scheme to fail, but accepted that there could be legal hurdles surrounding intellectual property rights and contracts. He explained that inevitably when discussing business or IP issues there will be differences of opinion. The CRT has approached around 20 leading pharmaceutical and biotech companies, and is c
'"/>




Page: 1 2

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
Other Medicine News:Health News:Baxter Reports Strong Third Quarter Sales and Earnings 2Health News:Baxter Reports Strong Third Quarter Sales and Earnings 3Health News:Baxter Reports Strong Third Quarter Sales and Earnings 4Health News:Baxter Reports Strong Third Quarter Sales and Earnings 5Health News:Baxter Reports Strong Third Quarter Sales and Earnings 6Health News:Baxter Reports Strong Third Quarter Sales and Earnings 7Health News:Baxter Reports Strong Third Quarter Sales and Earnings 8Health News:Baxter Reports Strong Third Quarter Sales and Earnings 9Health News:Baxter Reports Strong Third Quarter Sales and Earnings 10Health News:Baxter Reports Strong Third Quarter Sales and Earnings 11Health News:Baxter Reports Strong Third Quarter Sales and Earnings 12Health News:Baxter Reports Strong Third Quarter Sales and Earnings 13Health News:Baxter Reports Strong Third Quarter Sales and Earnings 14Health News:Baxter Reports Strong Third Quarter Sales and Earnings 15Health News:Baxter Reports Strong Third Quarter Sales and Earnings 16Health News:Baxter Reports Strong Third Quarter Sales and Earnings 17Health News:Baxter Reports Strong Third Quarter Sales and Earnings 18Health News:Baxter Reports Strong Third Quarter Sales and Earnings 19Health News:Baxter Reports Strong Third Quarter Sales and Earnings 20Health News:Baxter Reports Strong Third Quarter Sales and Earnings 21Health News:Baxter Reports Strong Third Quarter Sales and Earnings 22Health News:Baxter Reports Strong Third Quarter Sales and Earnings 23Health News:Baxter Reports Strong Third Quarter Sales and Earnings 24Health News:Baxter Reports Strong Third Quarter Sales and Earnings 25Health News:Baxter Reports Strong Third Quarter Sales and Earnings 26Health News:Baxter Reports Strong Third Quarter Sales and Earnings 27Health News:Baxter Reports Strong Third Quarter Sales and Earnings 28Health News:XTend Medical (XDMC) Adds New Bluetooth(R) Telemedicine Products From A&D Medical 2Health News:Holiday Gifts That Help Fight Alzheimer's Disease 2Health News:QLT announces Visudyne(R) sales for third quarter and provides Visudyne sales guidance for 2007 2Health News:QLT announces Visudyne(R) sales for third quarter and provides Visudyne sales guidance for 2007 3Health News:Practices in Health & Disability Insurance - The Lives & Wealth They Cost America 2
Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 2HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 3AMERIGROUP Corporation Names Two New Executives 58138 1AMERIGROUP Corporation Names Two New Executives 58138 2AMERIGROUP Corporation Names Two New Executives 58138 3Bubble Trouble Team Hits the Lab for Good Hygiene 58133 1Bubble Trouble Team Hits the Lab for Good Hygiene 58133 2Bubble Trouble Team Hits the Lab for Good Hygiene 58133 3Bubble Trouble Team Hits the Lab for Good Hygiene 58133 4Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31 2009 14227 1Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31 2009 14227 2Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31 2009 14227 3
Other Medicine Technology:New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 2New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 3New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 4New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 5Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 2Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 3Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 4Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 5Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 6Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 7